Basit öğe kaydını göster

dc.contributor.authorBozkus, Yusuf
dc.contributor.authorDemir, Canan
dc.contributor.authorAnil, Cuneyd
dc.contributor.authorMousa, Umut
dc.contributor.authorKut, Altug
dc.contributor.authorNar, Asli
dc.contributor.authorTutuncu, Neslihan B.
dc.date.accessioned2019-05-12T14:45:13Z
dc.date.available2019-05-12T14:45:13Z
dc.date.issued2018
dc.identifier.issn1011-7571
dc.identifier.urihttps://www.karger.com/Article/Pdf/486748
dc.identifier.urihttp://hdl.handle.net/11727/3268
dc.description.abstractObjective: The objective of this study was to assess the anti-proliferative pleiotropic effects of statins on thyroid function, volume, and nodularity. Subjects and Methods: One hundred and six hyperlipidemic patients were included in this prospective study. The 69 patients in the statin groups received atorvastatin (16 received 10 mg and 18 received 20 mg) or rosuvastatin (20 received 10 mg and 15 received 20 mg). The 37 patients in the control group, assessed as not requiring drugs, made only lifestyle changes. Upon admission and after 6 months, all patients were evaluated by ultrasonography as well as for lipid variables (total cholesterol, high-and low-density lipoprotein cholesterol, and triglycerides) and thyroid function and structure. Results: After 6 months, no differences in thyroid function, thyroid volume, the number of thyroid nodules, or nodule size were observed in the statin and control groups. In a subgroup analysis, total thyroid volume had decreased more in patients receiving 20 mg of rosuvastatin than that in the control group (p < 0.05). Maximum nodule size had decreased more in those receiving 10 mg of rosuvastatin (p < 0.05). Conclusions: Our results suggest an association between rosuvastatin treatment and smaller thyroid volume and maximum nodule diameter; this could be attributable to the antiproliferative effects of statin therapy on the thyroid. (C) 2018 The Author(s) Published by S. Karger AG, Baselen_US
dc.language.isoengen_US
dc.relation.isversionof10.1159/000486748en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHyperlipidemiaen_US
dc.subjectHMG-CoA reductase inhibitoren_US
dc.subjectStatinsen_US
dc.subjectAtorvastatinen_US
dc.subjectRosuvastatinen_US
dc.subjectThyroid volumeen_US
dc.subjectThyroid noduleen_US
dc.titleDo Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Studyen_US
dc.typearticleen_US
dc.relation.journalMEDICAL PRINCIPLES AND PRACTICEen_US
dc.identifier.volume27en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage7en_US
dc.identifier.wos000430508000001en_US
dc.identifier.scopus2-s2.0-85045840411en_US
dc.contributor.pubmedID29402848en_US
dc.contributor.orcID0000-0002-6976-6659en_US
dc.contributor.orcID0000-0003-0998-8388en_US
dc.contributor.orcID0000-0002-8078-9376en_US
dc.contributor.orcID0000-0002-1816-3903en_US
dc.contributor.orcID0000-0003-3802-9733en_US
dc.contributor.orcID0000-0003-0776-8349en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAA-5419-2021en_US
dc.contributor.researcherIDAAA-2743-2021en_US
dc.contributor.researcherIDI-1735-2018en_US
dc.contributor.researcherIDAAK-4857-2021en_US
dc.contributor.researcherIDABG-5027-2020en_US
dc.contributor.researcherIDA-2550-2015en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster